$34.04
-0.45-1.3%
마지막 업데이트: Oct 26, 4:00 PM
Benzinga
Benzinga
Benzinga
화요일, 10월 27
Benzinga
© 2026 Benzinga | All Rights Reserved
UroGen Pharma (URGN) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
| Metric | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $-0.31 | $-0.50 | $-0.57 | $-0.70 |
| Actual | $-0.28 | $-0.47 | $-0.54 | $-0.69 |
| Surprise | +9.68% | +6.00% | +5.26% | +1.43% |
| Revenue | ||||
| Estimate | $62.1M | $44.6M | $38.2M | $31.9M |
| Actual | $72.5M | $51.0M | $37.8M | $27.5M |
| Surprise | +16.7% | +14.3% | -0.88% | -13.7% |
| Metric | Q3 '26E | Q4 '26E | Q1 '27E | Q2 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $0.15 | $0.32 | $0.15 | $0.26 |
| Revenue | ||||
| Consensus | $90.2M | $107.3M | — | — |
| 회계 분기 | 보고된 날짜 | 실제 EPS | 예상 EPS | 놀라다 % |
|---|---|---|---|---|
| Q2 | Aug 5, 2026 | $-0.28 | $-0.31 | 9.68 % |
| Q1 | May 6, 2026 | $-0.47 | $-0.50 | 6.00 % |
| Q4 | Mar 2, 2026 | $-0.54 | $-0.57 | 5.26 % |
| Q3 | Nov 6, 2025 | $-0.69 | $-0.70 | 1.43 % |
| 회계 분기 | 보고된 날짜 | 실제 수익 | 예상 수익 | 놀라다 % |
|---|---|---|---|---|
| Q2 | Aug 5, 2026 | $72.46M | $62.10M | 16.7 % |
| Q1 | May 6, 2026 | $50.96M | $44.57M | 14.3 % |
| Q4 | Mar 2, 2026 | $37.84M | $38.17M | -0.88 % |
| Q3 | Nov 6, 2025 | $27.50M | $31.87M | -13.7 % |